IBRX ImmunityBio Inc: Enterprise Value-to-Revenue Multiple

Public company logo of immunitybio.com (IBRX)

ImmunityBio, Inc. (IBRX) generates revenue through the commercial implementation of ANKTIVA therapy for the treatment of bladder cancer. Clinics and insurance funds provide cash inflows via payments for this innovative treatment. Upgraded bioreactors at the company's own plants guarantee the production of large volumes. The total cost-to-revenue ratio reflects the impact of monetary policy, with 44313.14 recorded as the baseline value.

Company Value to Revenue: ImmunityBio Inc (IBRX) for 11/23/2025 - 11/19/2026

immunitybio.com - analytical breakdowns and key metrics (IBRX)

- share price and consensus valuation forecast:
Initial company analysis:ImmunityBio, Inc. IBRX
Product sample of ImmunityBio, Inc.

For an investor in ImmunityBio, Inc. (IBRX), a leader in T-cell activation for cancer therapy, this indicator serves as a tool to compare market capitalization with actual sales volume. By analyzing the EV/Sales multiple history, which accounts for net debt, one can assess the premium the market currently prices in for the company's breakthrough bladder cancer treatment technologies relative to its generated revenue.

Competitor analysis for ImmunityBio, Inc.

IMCR (immunocore.com) - Company Value to Revenue Ratio|Janux Corp (JANX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Arcus Bio (RCUS)|Company Value to Revenue ZYME|TNGX - Enterprise Value-to-Sales Ratio|Company Value to Revenue IOVA (Iovance)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP